Searched for
BEVACIZUMAB
Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drugBiocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's...11 Apr, 2025, 09.33 AM IST- Biocon shares fall 6% after Q2 net profit dives 84%. What should investors do?Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...31 Oct, 2024, 11.36 AM IST
- Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plantBiocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patient...24 Jun, 2024, 11.43 AM IST
- Biocon Biologics focusing on market share gains of biosimilars in key marketsBiocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...13 Feb, 2024, 03.43 PM IST
- USFDA issues CRL for Bevacizumab license application moved by Viatris: Biocon"The USFDA has issued a CRL for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan)," a company sp...12 Feb, 2023, 08.01 PM IST
- Biocon climbs 4% as pharma giant’s arm launches cancer treatment product AbevmyBiocon’s share price climbed to a high of Rs 334.70 as against Rs 322.95 at previous close on the BSE.Abevmy is a recombinant humanized mon...20 May, 2022, 12.32 PM IST
- Biocon Biologics, Viatris receive approval for cancer drugAbevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma,...26 Apr, 2021, 11.04 AM IST
- Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to AvastinAbevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cance...01 Mar, 2021, 10.35 AM IST
- US FDA accepts Biocon's cancer drug application for reviewBiocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...09 Mar, 2020, 10.13 AM IST
- Cipla ties up with Roche to sell 2 cancer drugs in IndiaThe pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India.27 Feb, 2018, 10.20 PM IST
- Biocon shares gains on cancer drug launchA biosimilar is a near copy of an original complex biologic drug.23 Nov, 2017, 06.51 PM IST
- Intas launches biosimilar Bevacizumab with aggressive pricingBiosimilar drugs are the follow on versions of biologic drugs which are composed of sugars, proteins, nucleic acids or complex combinations...04 Oct, 2017, 08.40 PM IST
- Biocon Q1 net profit slumps 51 per cent to Rs 81 croreThe company had posted a net profit of Rs 166.6 crore for the corresponding quarter of the previous fiscal, Biocon said in a BSE filing.27 Jul, 2017, 09.09 PM IST
- Reliance Lifesciences launches world's first biosimilar used to treat advanced cancersIn 2014, Reliance had entered into a similar arrangement with Torrent Pharma to sell copies of three drugs -- rituximab, adalimumab and cet...10 Jun, 2016, 03.05 AM IST
- Delhi High Court asks Roche to explain lawsuit over Avastin copyRoche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to b...24 May, 2016, 09.39 PM IST
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.21 May, 2016, 01.14 PM IST
- Indian drug regulator backs off over use of Roche’s AvastinThe Drug Controller General of India has passed an order removing an alert notice for the use of Roche’s Avastin (bevacizumab) injection to...12 Mar, 2016, 11.49 PM IST
Load More
